...
【24h】

Novel genes in primary aldosteronism

机译:原发性醛固酮增多症中的新基因

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose of review: Novel high-throughput genetic techniques have increased the pace of discoveries in the field of primary aldosteronism. Mutations in the potassium channel gene KCNJ5 are a cause of familial and sporadic forms of primary aldosteronism with around 30-40% of aldosterone-producing adenomas being affected by somatic mutations. Recent findings: Exome sequencing of tumors without KCNJ5 mutations revealed genetic alterations in the ATPases ATP1A1 and ATP2B3, with a combined prevalence of 5-7%. Mutations in the gene encoding a subunit of the Ca2+ channel Cav1.3 (CACNA1D) were described with a prevalence of 5-8%. In addition, a new syndrome consisting of primary aldosteronism, seizures, and neuromuscular disease with germline CACNA1D mutations could be identified. All these genetic variants enhance Ca 2+-mediated signalling and steroidogenesis in affected glomerulosa cells and provide the molecular basis for autonomous aldosterone secretion. Furthermore, the pattern of genetic alterations allows for subgrouping of patient cohorts with potentially distinct clinical features including sex and age distribution as well as endocrine and cardiovascular endpoints. Summary: Altogether in around 50% of aldosterone-producing adenomas, a somatic point mutation can be identified as the underlying genetic cause. These findings will provide the framework for potential identification of new biomarkers and therapeutic targets of this most common form of secondary hypertension.
机译:审查目的:新型高通量遗传技术提高了原发性醛固酮增多症领域的发现速度。钾通道基因KCNJ5中的突变是原发性醛固酮增多症的家族和散发性形式的原因,约30-40%的醛固酮生成腺瘤受到体细胞突变的影响。最近的发现:没有KCNJ5突变的肿瘤的外显子组测序显示ATPases ATP1A1和ATP2B3的遗传改变,合并患病率为5-7%。描述了编码Ca2 +通道Cav1.3(CACNA1D)亚基的基因中的突变,患病率为5-8%。此外,可以鉴定出一种新的综合征,包括原发性醛固酮增多症,癫痫发作和具有种系CACNA1D突变的神经肌肉疾病。所有这些遗传变异增强了受影响的肾小球细胞中Ca 2+介导的信号传导和类固醇生成,并为醛固酮的自主分泌提供了分子基础。此外,遗传改变的模式允许将具有潜在不同临床特征(包括性别和年龄分布以及内分泌和心血管终点)的患者队列分组。摘要:在大约50%的醛固酮生成腺瘤中,体细胞点突变可被确定为潜在的遗传原因。这些发现将为潜在的识别继发性高血压的最常见形式的新生物标志物和治疗靶标提供框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号